Trials / Terminated
TerminatedNCT02788578
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the PRELUDE study is to describe the use of lanreotide Autogel® (LAN ATG) combined with Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of progressive neuroendocrine tumours located in the lung or in the digestive system as there is currently limited data on these treatments used together for these types of neuroendocrine tumours.
Conditions
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2016-06-02
- Last updated
- 2018-12-21
Locations
12 sites across 5 countries: Australia, France, Germany, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT02788578. Inclusion in this directory is not an endorsement.